Ceftazidime

Ceftazidime Impurities

Ceftazidime impurities consist of structurally related analogs, residual solvents, and degradation products formed under stress conditions such as hydrolysis, oxidation, and photolysis. As a third-generation cephalosporin antibiotic used to treat serious Gram-negative bacterial infections, impurity profiling is essential to maintain therapeutic efficacy and patient safety. Degradation pathways typically involve hydrolytic cleavage of the beta-lactam ring, isomerization of the double bond, and oxidative breakdown of the aminothiazole and pyridinium moieties. All impurities are structurally characterized and qualified in accordance with ICH guidelines for toxicological assessment and analytical validation.

Ceftazidime EP Impurities

Pharmacopeial and non-pharmacopeial Ceftazidime impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and long-term stability studies. EP traceable materials are supplied with validated analytical data, including purity, structural confirmation, and spectral characterization.

Ceftazidime Related Compounds

Structurally related compounds and synthetic analogs associated with Ceftazidime are included for use in impurity identification, toxicological qualification, and regulatory submission. These related substances are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations. They are essential for understanding the impurity profile and ensuring compliance with regulatory limits.

Ceftazidime Impurity Reference Standards

Ceftazidime impurity reference standards are provided with validated analytical data, including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.